RxDoctor Payments Data

Andrew Davis, MD

Ophthalmology · Williamsburg, VANPI 1700273539

Payments from drug & device makers

$2,458in general payments, 2019–2025

Across 72 payments — averaging $34.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$917
  • Biotissue Holdings Inc.$269
  • AbbVie$217
  • Sun Pharmaceutical Industries Inc.$161
  • NEW World Medical,inc.$159
  • Shire North American Group Inc$125
  • plus $610 from 15 others

What the payments were for

  • Food & beverage$2,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,458 in reported general payments places this provider in the 70th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$491,162
Medicare patients
1,813
Services billed
5,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost257$162,562
RestasisCyclosporine66$72,892
CombiganBrimonidine Tartrate/Timolol60$22,979
Cyclosporine34$21,504
Travoprost62$15,402
VyzultaLatanoprostene Bunod23$14,002
Latanoprost753$10,360
RocklatanNetarsudil Mesylat/Latanoprost16$8,674
Prednisolone Acetate231$7,445
ProlensaBromfenac Sodium13$7,114
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat257$6,783
Timolol Maleate259$4,449
Brinzolamide13$3,930
Alphagan PBrimonidine Tartrate12$3,929
Loteprednol Etabonate25$3,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$217$262,363395 claims
Bausch & Lomb Americas Inc.Vyzulta$118$14,00223 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$47$10,75638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →